NEWRON PHARMACEUT. EO-,20 financial statements, including revenue, expenses, profit, and loss
The total revenue of NP5 for the last semiannual is 3.67 M EUR, and it's 33.76% lower compared to the previous semiannual. The net income of H2 23 is -9.56 M EUR.